http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103690530-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aa290cfbc4cd90be40bdc3dfa6829f54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-37 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-04 |
| filingDate | 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_73469e186f17a3bc9c17131456cddcdc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2eb0bc42bb6619a82548958b90a8e48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2da2b59acd29fb1991a3e69afbd3ceb5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3697db9e9df0f7d999c020de0281ce7c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e35c4e03ef149841a79318922b96392d |
| publicationDate | 2014-04-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103690530-A |
| titleOfInvention | Application of ethyl 6-chlorocoumarin-3-carboxylyl L-theanine and the like in preparation of product used for preventing and treating disease such as cancers |
| abstract | The invention relates to the field of medical technology. Ethyl 6-chlorocoumarin-3-carboxylyl L-theanine, a novel synthetic compound, can inhibit the growth and invasion of cancer cells of human lung cancer, breast cancer, liver cancer, gastric cancer, colon cancer, prostatic cancer, pancreatic cancer, cervical cancer, lymphadenoma, leucocythemia, melanoma, and the like, and can remarkably inhibit the growth and metastasis of the tumors in a body, with an inhibiting effect exceeding the inhibiting effects of anti-cancer drugs. The mechanism of action involves the down regulation inhibition of the bonding of the receptors which are closely related to growth, invasion and metastasis of the tumors, signal transduction regulation and control proteins, the kinase level and a nuclear factor with DNA, and also upper regulation of factors such as cancer-inhibiting proteins and cell cycle inhibition proteins. The ethyl 6-chlorocoumarin-3-carboxylyl L-theanine can directly inhibit the activity of histone deacetylase, the activity of histonemethylferase EZH2, and combination of a inflammatory factor NF-[Kabba]B and DNA. The activity of the ethyl 6-chlorocoumarin-3-carboxylyl L-theanine exceeds the activity of clinical anti-cancer drugs. The invention provides new applications of the ethyl 6-chlorocoumarin-3-carboxylyl L-theanine in prevention and treatment of diseases such as tumors, inflammation, heart and cerebral vessels and immunodeficiency. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020011607-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104623676-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104623676-B |
| priorityDate | 2012-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 208.